Stratec SE
XETRA:SBS

Watchlist Manager
Stratec SE Logo
Stratec SE
XETRA:SBS
Watchlist
Price: 26.45 EUR -4.51% Market Closed
Market Cap: 321.5m EUR
Have any thoughts about
Stratec SE?
Write Note

Stratec SE
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Stratec SE
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Stratec SE
XETRA:SBS
Total Current Liabilities
€93.4m
CAGR 3-Years
24%
CAGR 5-Years
16%
CAGR 10-Years
18%
Carl Zeiss Meditec AG
XETRA:AFX
Total Current Liabilities
€507.4m
CAGR 3-Years
13%
CAGR 5-Years
12%
CAGR 10-Years
10%
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Total Current Liabilities
€99.9m
CAGR 3-Years
28%
CAGR 5-Years
24%
CAGR 10-Years
12%
Siemens Healthineers AG
XETRA:SHL
Total Current Liabilities
€11.2B
CAGR 3-Years
4%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Draegerwerk AG & Co KGaA
XETRA:DRW8
Total Current Liabilities
€948.4m
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
3%
Sartorius AG
XETRA:SRT
Total Current Liabilities
€977m
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
15%
No Stocks Found

Stratec SE
Glance View

Market Cap
321.5m EUR
Industry
Health Care

STRATEC SE engages in the design and manufacture of automated analyzer systems in the fields of clinical diagnostic and biotechnology. The company is headquartered in Birkenfeld, Baden-Wuerttemberg and currently employs 1,398 full-time employees. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.

SBS Intrinsic Value
57.94 EUR
Undervaluation 54%
Intrinsic Value
Price

See Also

What is Stratec SE's Total Current Liabilities?
Total Current Liabilities
93.4m EUR

Based on the financial report for Sep 30, 2024, Stratec SE's Total Current Liabilities amounts to 93.4m EUR.

What is Stratec SE's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
18%

Over the last year, the Total Current Liabilities growth was -4%. The average annual Total Current Liabilities growth rates for Stratec SE have been 24% over the past three years , 16% over the past five years , and 18% over the past ten years .

Back to Top